Eskd immunoglobulin response at 3 months post COVID-19 vaccination

ABSTRACT

Background: End stage kidney disease (ESKD) patients (pts) remain at high risk for COVID 19 infection. Inadequate post infection antibody response is reported in 10-11% of pts1. Current data is limited on ESKD post vaccination (vac)2 We report 3-month (mo) post vac response of ESKD pts receiving 2 doses of either Moderna or Pfizer vaccines. Methods: Twenty-six of 42 stable ESKD pts completed 2 doses of either Moderna or Pfizer vaccination at Salem VAMC or at their nursing home facility during mo 01/02-2021. 17/42 were not vaccinated (7 declined, 2 with COVID 19 infection, 6 acutely hospitalized) during that time. Antibody immune response testing using ADVIA Centaur COV2G automated 2-step sandwich immunoassay using indirect chemiluminescent technology and designed to detect the SARS-CoV-2 surface spike protein receptor binding domain (S1RBD) was completed in 05/2021. Measures obtained included reactivity to total SARS CoV-ab (IgM+ IgG) and IgG separately. Results: Please see table 1 for results Conclusions: ESKD vaccine response to COVID 19 after 3months was 96% for total immunoglobulin response (IgM and IgG) and 87.5% for total IgG antibody response compared to no reactivity in those nonvaccinated patients. Age and presence of diabetes did not significantly affect immune response. Approximately 12.5 % of patients had nonreactivity to IgG antibody after 3 months. Patients not developing an IgG response by 3 mo were found to have underlying immunosuppressive disease. ESKD with COVID 19 infection maintained IgG reactive response 3 months after active disease. Nonreactivity was seen in those neither infected nor vaccinated, suggesting that these patients have likely not been exposed to COVID 19 viral infection.